A Brief Overview of Current Drug Repurposing Approaches for COVID-19 Management
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19). In this sense, the repositioning drugs for new indications can offer a better risk-versus-reward trade-off when compared to other drug development strategies, given that it makes use of drugs whose safety profile are already understood. Nonetheless, this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Traektoriâ Nauki - 6(2020), 4, Seite 3001-3005 |
| Sprache: |
Englisch ; Russisch ; Ukrainisch |
|---|
| Beteiligte Personen: |
Pedro da Fonseca Soares Rodrigues [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiviral |
|---|
| doi: |
10.22178/pos.57-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ053523342 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ053523342 | ||
| 003 | DE-627 | ||
| 005 | 20230502061723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22178/pos.57-1 |2 doi | |
| 035 | |a (DE-627)DOAJ053523342 | ||
| 035 | |a (DE-599)DOAJcc9a56627494421e943f1a445826c7d6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus |a ukr | ||
| 100 | 0 | |a Pedro da Fonseca Soares Rodrigues |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Brief Overview of Current Drug Repurposing Approaches for COVID-19 Management |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19). In this sense, the repositioning drugs for new indications can offer a better risk-versus-reward trade-off when compared to other drug development strategies, given that it makes use of drugs whose safety profile are already understood. Nonetheless, this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it. | ||
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a antiviral | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a outbreak | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a healthcare | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Douglas Vieira Thomaz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Traektoriâ Nauki |d Altezoro s.r.o. (Slovak Republic) and Publishing Center "Dialog" (Ukraine), 2016 |g 6(2020), 4, Seite 3001-3005 |w (DE-627)DOAJ00010163X |x 24139009 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:4 |g pages:3001-3005 |
| 856 | 4 | 0 | |u https://doi.org/10.22178/pos.57-1 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cc9a56627494421e943f1a445826c7d6 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2413-9009 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 4 |h 3001-3005 | ||